How do pediatric peroxisomal disorders clinic nurses explain to Spanish-speaking parents why a boy with X-ALD who is completely asymptomatic and performing normally in school needs brain MRI surveillance every six months?

The explanation requires establishing what the six-month MRI surveillance is looking for and what it is not looking for, and specifically why it cannot be replaced by symptom monitoring. X-linked adrenoleukodystrophy (X-ALD) is caused by hemizygous mutations in the ABCD1 gene encoding the ALD protein (ALDP), a peroxisomal membrane transporter of the ATP-binding cassette superfamily. ALDP normally transports very-long-chain fatty acids (VLCFA) — particularly saturated C24:0 (tetracosanoic acid) and C26:0 (hexacosanoic acid) — into peroxisomes, where they undergo beta-oxidation. Without functional ALDP, VLCFA accumulate in plasma, red blood cells, and throughout the body's tissues including central nervous system white matter, adrenocortical cells, and Leydig cells. Elevated plasma VLCFA are the diagnostic biomarker. However, plasma VLCFA levels do not predict which boys with X-ALD will develop childhood cerebral ALD (CCALD) or when. The childhood cerebral form of X-ALD — CCALD — is an inflammatory demyelination syndrome that occurs in approximately thirty-five to forty percent of males with X-ALD between ages four and twelve. It is not a gradual worsening of VLCFA-related toxicity visible in blood tests. It is a distinct process in which the blood-brain barrier breaks down in the cerebral white matter, triggering an inflammatory cascade with T-lymphocyte and macrophage invasion that rapidly destroys myelin. The early phase of CCALD is entirely asymptomatic and entirely invisible to the parents. A boy in the early CCALD phase makes honor roll in school, plays soccer, shows no behavioral change, and has no detectable neurological abnormality on clinical examination. The process is visible only on brain MRI, where it appears as T2/FLAIR hyperintensity — a subtle white-matter signal change on MRI — beginning in the parieto-occipital white matter in approximately eighty percent of cases or the frontal white matter in twenty percent. This early signal is scored using the Loes scoring system: Loes score zero means a completely normal MRI; Loes 0.5 to three reflects very early signal change; Loes three to nine reflects moderate involvement; Loes greater than nine reflects significant disease. The critical clinical fact is that hematopoietic stem cell transplantation (HSCT) — the only treatment that halts CCALD progression — works only during a defined window: Loes score less than or equal to nine, neurological performance score of zero or one (no or minimal neurological deficit), and absence of extensive gadolinium enhancement on contrast MRI. HSCT works by replacing microglia — the brain's resident macrophages, which are derived from bone marrow — with donor cells that express functional ALDP. This gradually halts the inflammatory process that is destroying white matter. But HSCT itself is harmful if the inflammatory phase is already advanced. When Loes score exceeds nine, or when significant gadolinium enhancement indicating active inflammation is present, HSCT accelerates the inflammatory injury rather than halting it. There is no second-chance window. The window closes, and the patient declines without any further intervention available. The interval between onset of MRI signal change and loss of HSCT eligibility — from Loes 0.5 to Loes nine — is on average approximately twelve to eighteen months, but in aggressive CCALD it can be as short as six months. The six-month MRI surveillance interval means that a boy who was Loes zero at the last MRI and develops early signal change (Loes 0.5 to three) at five months will be caught within one month of the signal appearing — well within the transplant window. If the surveillance interval were twelve months, a boy who develops aggressive CCALD three months after a normal scan could have Loes greater than nine by the time of his next scheduled MRI and have already lost the transplant window. Symptom monitoring cannot replace MRI monitoring for two reasons. First, the early asymptomatic CCALD phase — Loes 0.5 to six — produces no behavioral, cognitive, or neurological changes that parents or teachers can detect. The MRI and the clinical exam are measuring different things. Second, by the time behavioral changes (irritability, declining school performance, hyperactivity) or neurological signs (gait changes, visual disturbance, handwriting deterioration) appear, CCALD is typically already at Loes seven or above — at the outer edge of or beyond the transplant window. The six-month MRI surveillance interval is not a precaution against a possible future problem. It is the treatment strategy. The entire chance of intervening before the window closes depends on the MRI being done on time.

How do pediatric peroxisomal disorders clinic nurses explain to Spanish-speaking parents why X-ALD adrenal insufficiency requires annual ACTH stimulation testing when the child looks completely well and has been stable on hydrocortisone for months without any crisis?

The explanation requires establishing that adrenal involvement in X-ALD is a progressive process that continues year after year regardless of how the child looks or how stable neurological surveillance appears, and that annual testing tracks a transition — from partial to complete adrenal insufficiency — that has no symptoms until it produces a crisis. VLCFA accumulate in the adrenal cortex as part of the systemic X-ALD disease. The adrenal cortex has three layers: the zona glomerulosa (which makes aldosterone, the mineralocorticoid), the zona fasciculata (which makes cortisol, the glucocorticoid), and the zona reticularis (which makes androgens). VLCFA accumulation is most destructive to the zona fasciculata and zona reticularis — the cortisol- and androgen-producing layers. Over years, VLCFA-laden cells in these zones undergo progressive lipid overload and cell death, reducing the total number of functional adrenocortical cells available to produce cortisol. The ACTH stimulation test measures adrenal reserve: the adrenal cortex is maximally stimulated by synthetic ACTH (cosyntropin, 250 micrograms intravenous), and cortisol production is measured at thirty and sixty minutes. A normal response is cortisol peak of eighteen micrograms per deciliter or higher. A result of eleven to seventeen micrograms per deciliter indicates partial adrenal insufficiency — the adrenal cortex is struggling but can still produce some cortisol under stress. A result below eleven micrograms per deciliter indicates complete adrenal insufficiency — the cortex cannot mount an adequate response. In X-ALD males, adrenal insufficiency precedes neurological symptoms in approximately fifty percent of cases and is the presenting feature at diagnosis before any neurological involvement in many boys identified clinically rather than through newborn screening. Critically, adrenal involvement in X-ALD progresses independently of neurological disease activity. A boy with X-ALD who has had consistently normal brain MRI for five consecutive years — meaning he has, so far, been in the lucky sixty to sixty-five percent of males who do not develop CCALD — can still be losing adrenocortical cells every year as VLCFA accumulate in the zona fasciculata. The neurological surveillance result and the adrenal function result measure two separate disease processes. A boy who tests at cortisol peak thirteen micrograms per deciliter at age five — borderline, partial insufficiency, managed with hydrocortisone — may have cortisol peak eight micrograms per deciliter at age seven (complete insufficiency, confirming the progression), and this progression occurs entirely silently: no change in energy, no change in appetite, no skin darkening that the parents would notice, no change in the child's appearance or behavior. The clinical danger is this: a child with complete adrenal insufficiency who develops any significant physiological stress — fever above thirty-eight-point-five degrees Celsius, a vomiting illness, a surgical procedure, significant physical trauma — cannot produce the cortisol surge that physiological stress demands. Cortisol is required for vascular tone maintenance, glucose mobilization, and the body's inflammatory response to acute illness. Without it, blood pressure falls, glucose drops, the child becomes progressively ill in a pattern that can be confused with the underlying illness (vomiting from the illness is also vomiting from adrenal crisis; fatigue is present in both). The adrenal crisis spiral — cortisol deficiency leading to nausea, vomiting worsening absorption failure, blood pressure falling, cardiovascular collapse — can occur within hours of a vomiting illness if the cortisol replacement dose is not tripled (the stress dosing rule: during significant illness, double or triple the hydrocortisone dose). Annual ACTH stimulation testing serves two purposes in X-ALD boys on hydrocortisone: it determines whether the partial insufficiency has progressed to complete insufficiency, which requires dose adjustment; and it guides the aldosterone component (fludrocortisone dosing), since zona glomerulosa destruction — which progresses more slowly than zona fasciculata — eventually causes salt-wasting that requires fludrocortisone titration. The child who looks completely well is not demonstrating that his adrenal cortex is stable. He is demonstrating that the hydrocortisone replacement is working. Annual ACTH testing monitors the function of the adrenal cortex that the hydrocortisone is replacing.

How do pediatric peroxisomal disorders clinic nurses explain to Spanish-speaking parents why their daughter who is a heterozygous X-ALD carrier and was told she cannot get the brain disease needs neurological follow-up and future adrenal monitoring?

The explanation requires unpacking the phrase 'girls cannot get the disease' and establishing what it is accurate about (childhood cerebral ALD) and what it is not accurate about (the full spectrum of ABCD1-related neurological and adrenal disease in females). X-linked adrenoleukodystrophy is caused by mutations in the ABCD1 gene on the X chromosome. Males have one X chromosome and one Y chromosome. A male with a pathogenic ABCD1 mutation on his only X chromosome is hemizygous — every cell in his body expresses only the mutant ABCD1 allele. He has no functional ALDP produced anywhere. VLCFA accumulate in all ABCD1-expressing tissues without any genetic backup. This is why X-ALD in males produces disease across the full spectrum — CCALD (the childhood cerebral form), adrenomyeloneuropathy (the adult axonal form), and adrenal insufficiency. Females have two X chromosomes. A female with an ABCD1 mutation on one X chromosome and a normal ABCD1 allele on the other X chromosome is heterozygous. In every cell in her body, one of the two X chromosomes is randomly inactivated during embryonic development (the process called X-inactivation or Lyonization). In cells where the X chromosome carrying the normal ABCD1 allele is active, the cell produces functional ALDP and can import VLCFA into peroxisomes. In cells where the X chromosome carrying the mutant ABCD1 allele is active, the cell produces no functional ALDP. Across the billions of cells in the female carrier's nervous system, both populations of cells exist simultaneously. The random distribution of X-inactivation patterns across individuals means that some female carriers have a high proportion of cells with normal ABCD1 active (and may remain neurologically unaffected lifelong) while others have a skewed X-inactivation toward the mutant allele — many or most neurons and axons expressing nonfunctional ALDP. The statement 'girls cannot get the disease' is accurate for one specific X-ALD disease: childhood cerebral ALD (CCALD). CCALD requires the profound, sustained VLCFA accumulation that occurs only in hemizygous males with no functioning ABCD1. The brain's inflammatory response that drives CCALD appears to need a threshold of VLCFA accumulation that heterozygous females, with their functional ABCD1-expressing cell population, essentially never reach. CCALD in female ABCD1 carriers occurs in fewer than one percent of cases — effectively an extremely rare occurrence rather than a clinical concern that drives surveillance decisions. This is the fact the parents were accurately told. What they were not told is that adrenomyeloneuropathy (AMN) — the spinal cord form of X-ALD, which is the most common neurological manifestation in adults — affects approximately sixty-five to seventy percent of female ABCD1 carriers by age sixty. AMN is caused by slowly progressive axonal degeneration in the long corticospinal and spinocerebellar tracts of the spinal cord — a mechanism distinct from CCALD's inflammatory white-matter process. In females, AMN typically begins in the third or fourth decade of life and presents as gradually progressive leg stiffness (spastic paraparesis), difficulty walking, bladder urgency and incomplete emptying, and sensory loss in the feet. The progression is typically slower in females than in hemizygous males with AMN (who develop it in essentially one hundred percent of cases by middle age), but the majority of female carriers do develop clinically significant myelopathy over their lifetime. Annual neurological follow-up for a fourteen-year-old female carrier is not watching for CCALD — she is essentially not at risk for it. It is establishing a baseline neurological examination that will be used in her twenties, thirties, and forties to detect the early subtle signs of AMN (changes in gait, reflexes, bladder function) before they become disabling; it is building the family's understanding of AMN so that when early symptoms appear they recognize them as disease manifestations that can be addressed rather than as unrelated symptoms to be attributed to other causes; and it is discussing reproductive planning — because each son she may have as an adult has a fifty percent chance of inheriting the ABCD1 mutation and being at risk for CCALD and AMN, and preimplantation genetic testing (PGT) and prenatal diagnosis are options that require advance understanding to use. The adrenal component — approximately one percent of female ABCD1 carriers develop adrenal insufficiency — is less common than AMN but real enough to warrant periodic assessment as she ages.

What are the key clinical Spanish phrases for explaining X-ALD management to Spanish-speaking families in the pediatric peroxisomal disorders clinic, covering MRI surveillance, adrenal insufficiency monitoring, and female carrier follow-up?

Key clinical Spanish phrases for the pediatric X-ALD and peroxisomal disorders outpatient clinic, organized by the three communication challenges. For explaining CCALD MRI surveillance necessity: 'Miguel se ve completamente normal porque en este momento está completamente normal. Lo que hace la resonancia cada seis meses no es ver síntomas — los síntomas llegan demasiado tarde. La resonancia busca el primer cambio en la sustancia blanca del cerebro que puede aparecer meses antes de que Miguel sienta cualquier cosa. Ese cambio es la señal de que hay un proceso inflamatorio empezando en el cerebro. Si vemos ese cambio temprano — cuando la resonancia muestra un puntaje de cero-punto-cinco a tres — hay un trasplante de médula ósea que puede detener ese proceso. Ese trasplante funciona solo en esa ventana. Si perdemos esa ventana — porque la resonancia se hizo tarde, o se pospuso, o el cambio progresó demasiado antes del próximo control — el trasplante ya no funciona y Miguel entraría en un deterioro que no tiene tratamiento. El intervalo de seis meses no es precaución extra. Es el intervalo máximo que nos permite atrapar ese cambio antes de que la ventana se cierre. Postponer la resonancia no es seguro en Miguel.' (Miguel looks completely normal because right now he is completely normal. What the MRI every six months does is not look for symptoms — symptoms come too late. The MRI looks for the first change in the brain's white matter that can appear months before Miguel feels anything. That change is the signal that an inflammatory process is starting in the brain. If we see that change early — when the MRI shows a score of 0.5 to 3 — there is a bone marrow transplant that can stop that process. That transplant works only in that window. If we miss that window — because the MRI was done late, or was postponed, or the change progressed too much before the next check — the transplant no longer works and Miguel would enter a deterioration that has no treatment. The six-month interval is not extra precaution. It is the maximum interval that allows us to catch that change before the window closes. Postponing the MRI is not safe for Miguel.) For explaining X-ALD adrenal insufficiency annual ACTH testing: 'Alejandro se ve bien porque el hidrocortisona está haciendo el trabajo de la glándula suprarrenal. La prueba de ACTH no verifica que Alejandro se vea bien — eso ya lo vemos. La prueba mide cuánto cortisol puede producir la glándula suprarrenal por sí sola cuando la estimulamos al máximo. En la enfermedad de Alejandro, los ácidos grasos de cadena muy larga se acumulan en las células de la glándula suprarrenal y las destruyen progresivamente — año tras año, independientemente de cómo estén los resultados neurológicos. El año pasado la respuesta fue 13. Este año fue 8 — la glándula respondió menos. Eso nos dice que necesitamos ajustar la dosis del hidrocortisona. Sin la prueba anual, no sabríamos que la glándula está perdiendo más células cada año hasta que Alejandro tuviera una crisis durante una enfermedad y no pudiéramos explicar por qué. La enfermedad de la glándula suprarrenal y la enfermedad del cerebro son dos procesos diferentes en Alejandro. Los resultados de la resonancia no nos dicen cómo está la glándula. Solo la prueba de ACTH nos dice eso.' (Alejandro looks well because hydrocortisone is doing the work of the adrenal gland. The ACTH test does not verify that Alejandro looks well — we can already see that. The test measures how much cortisol the adrenal gland can produce on its own when we stimulate it maximally. In Alejandro's disease, very-long-chain fatty acids accumulate in adrenal gland cells and destroy them progressively — year after year, independently of how the neurological results are. Last year the response was 13. This year it was 8 — the gland responded less. That tells us we need to adjust the hydrocortisone dose. Without the annual test, we would not know the gland is losing more cells each year until Alejandro had a crisis during an illness and we could not explain why. The adrenal gland disease and the brain disease are two different processes in Alejandro. The MRI results do not tell us how the gland is doing. Only the ACTH test tells us that.) For explaining female X-ALD carrier neurological follow-up: 'Lo que le dijeron era correcto para una parte de la enfermedad. La forma infantil — la que afecta el cerebro de los niños entre los cuatro y los doce años — casi exclusivamente les ocurre a los niños varones que tienen la mutación en el único cromosoma X que tienen. Sofía tiene dos cromosomas X. En uno tiene la mutación. En el otro tiene la copia normal. Las células que usan el cromosoma normal producen la proteína correcta. Eso es por qué la forma infantil de la enfermedad no aplica a Sofía. Pero hay otra forma de la enfermedad — la adrenomieloneuropatía — que afecta la médula espinal, no el cerebro. Esa forma no requiere la misma acumulación masiva que la forma infantil. Aproximadamente el sesenta y cinco por ciento de las mujeres que tienen la misma mutación que Sofía desarrollan algún grado de rigidez en las piernas, dificultad para caminar, y problemas para la vejiga entre los cuarenta y los sesenta años, dependiendo de qué proporción de sus células usaron el cromosoma con la mutación. El seguimiento anual ahora, cuando Sofía tiene catorce años, establece la línea de base — cómo camina, los reflejos, la sensación en los pies — para que en veinte años, si algo empieza a cambiar, tengamos con qué comparar. No estamos buscando la forma infantil. Estamos preparándonos para los cuarenta años de Sofía.' (What they told you was correct for one part of the disease. The childhood form — the one that affects boys' brains between ages four and twelve — almost exclusively occurs in boys who have the mutation on the only X chromosome they have. Sofía has two X chromosomes. On one she has the mutation. On the other she has the normal copy. The cells that use the normal chromosome produce the correct protein. That is why the childhood form of the disease does not apply to Sofía. But there is another form of the disease — adrenomyeloneuropathy — that affects the spinal cord, not the brain. That form does not require the same massive accumulation as the childhood form. Approximately sixty-five percent of women who have the same mutation as Sofía develop some degree of leg stiffness, difficulty walking, and bladder problems between ages forty and sixty, depending on what proportion of their cells used the chromosome with the mutation. The annual follow-up now, when Sofía is fourteen, establishes the baseline — how she walks, the reflexes, the sensation in her feet — so that in twenty years, if something starts to change, we have something to compare to. We are not looking for the childhood form. We are preparing for Sofía's forties.)

What are the most important communication challenges specific to Spanish-speaking families in the pediatric X-ALD and peroxisomal disorders outpatient clinic that standard translated handouts do not address?

Three structural communication challenges arise across the X-ALD pediatric clinic encounters and are inadequately addressed by translated handouts alone. The first is the asymptomatic-is-not-safe paradox in CCALD surveillance. Families of boys with X-ALD who have had three, four, or five consecutive normal brain MRIs reasonably develop a model in which the consecutive normals mean their son is probably in the lucky sixty percent who will not develop CCALD, or that his normal status is confirmed by the normals to date. Both conclusions are clinically dangerous. The first is a misapplication of cumulative probability: each six-month surveillance interval is not a confirmation of prior safety but a new assessment of current status; a boy who has had five consecutive normal MRIs is not less likely to develop CCALD at the sixth interval. The second is a misapplication of the significance of normalcy: a normal MRI means CCALD has not started yet, not that it cannot start at the next interval. The critical concept that the handout cannot adequately convey without a nurse-led conversation is the irreversibility of missing the window. Parents whose son's cancer screening came back normal feel reassured. Parents whose son's CCALD surveillance came back normal need to feel that the next scan is equally critical — because the consequence of a false-security response (delaying the next scan 'since he's been fine') is not a missed early detection of a treatable cancer; it is a missed HSCT transplant window that cannot be reopened. The six-month interval is not the interval the system is comfortable with — it is the maximum defensible gap, and extending it, even by two months, carries a real clinical risk that grows with each delay. The second challenge is explaining the double disease model in X-ALD. Families who have navigated the CCALD surveillance model for years — and whose son has made it through the pediatric CCALD risk period with normal MRIs at age twelve — often relax under the assumption that the difficult part is over. The next communication challenge is explaining that neurological disease in X-ALD is not over at age twelve; it has entered a different phase. Adrenomyeloneuropathy — axonal degeneration in long spinal cord tracts — develops in essentially one hundred percent of males with X-ALD who live into adulthood, with symptoms typically beginning between ages twenty and forty. The mechanisms are different (axonal degeneration from VLCFA toxicity, not inflammatory demyelination), the tempo is different (years of gradual progression rather than months of rapid decline), and the surveillance accordingly shifts from six-monthly brain MRI to periodic neurological examination and nerve conduction studies. A family that understood CCALD surveillance is the whole disease is a family that is not prepared for the AMN conversation at a transition clinic visit. The third challenge — most unique to X-ALD among rare metabolic diseases — is the carrier female conversation. The phrase 'your daughter is a carrier' is routinely heard by families of boys with X-linked diseases and routinely carries the implication 'she will not be affected.' In X-ALD, that implication is accurate for one specific outcome (CCALD) and inaccurate for the most common lifetime neurological outcome (AMN). Female carriers are not simply genetic conduits for the next generation's X-ALD risk. They are individuals who have approximately a two-in-three chance of developing a progressive neurological disease in midlife, and approximately a one in one hundred chance of developing adrenal insufficiency. The neurometabolic clinic's job with a fourteen-year-old female carrier is not to diagnose or treat an imminent disease. It is to establish a relationship, build a baseline, convey an accurate long-term risk picture, and begin the reproductive planning conversation early enough that it is not rushed when she reaches adulthood. Spanish-speaking families — who may have cultural frameworks about female health that deprioritize specialist follow-up for children who look healthy — benefit from hearing this framing clearly and early from a nurse who has time to explain what 'approximately sixty-five percent lifetime risk' means in practical terms: not that Sofía will definitely develop AMN, but that her lifetime surveillance is as important for her health as her brother's MRI surveillance is for his.

Spanish for pediatric peroxisomal disorders clinic nurses — the parents who cannot understand why their son with X-ALD who is making honor roll and playing soccer needs a brain MRI every six months not knowing childhood cerebral ALD transitions silently from a normal MRI to fulminant inflammatory demyelination in as few as six months and the only effective treatment hematopoietic stem cell transplantation works only during the first three months of MRI signal change before the transplant window closes permanently; the parents who cannot understand why their son on hydrocortisone for X-ALD adrenal insufficiency who looks completely well needs annual ACTH stimulation testing not knowing VLCFA accumulation destroys adrenocortical cells progressively and independently of neurological disease making the transition from partial to complete adrenal insufficiency an annual monitoring question not a one-time determination; and the parents who cannot understand why their daughter who was told she cannot get the brain disease needs neurological follow-up not knowing approximately sixty-five percent of female X-ALD carriers develop adrenomyeloneuropathy-type spinal cord disease by age sixty and the statement girls are safe from X-ALD is accurate only for the childhood cerebral form

Pediatric X-ALD nursing requires explaining three management decisions that each contradict what the family can observe directly. A nine-year-old on the academic honor roll, playing recreational soccer, with a completely normal neurological examination, whose family has driven to the MRI unit six times in three years without a single abnormal result, and who is being asked to come back in six months for the same scan. A seven-year-old who looks completely healthy, has never been hospitalized for an adrenal crisis, and whose cortisol replacement dose has not changed in four months, whose parents are now being asked to schedule an ACTH stimulation test with a twenty-four-hour intravenous infusion. And a fourteen-year-old girl whose younger brother has X-ALD, whose family was told by the genetics team at his diagnosis that girls carry the gene but don’t get the disease, who is now sitting in an annual neurological follow-up that her parents cannot understand the rationale for.

Each family is in the same structural position: they received incomplete information not because anyone lied to them, but because the complete information requires explaining mechanisms that clinical summaries routinely omit. The parents of the asymptomatic nine-year-old were told their son needed surveillance, but were not told that the surveillance is not watching for symptoms — it is watching for an MRI signal change that precedes symptoms by months and that, if missed, permanently forecloses the only effective treatment. The parents of the seven-year-old on hydrocortisone were told that adrenal function needs to be checked, but were not told that the adrenal gland is being destroyed by VLCFA accumulation year after year as a process completely separate from the neurological disease their son’s brain MRIs have so far reassured them about. And the parents of the fourteen-year-old carrier were told an accurate fact — childhood cerebral ALD does not affect girls — that they correctly internalized but that does not capture the sixty-five percent lifetime probability of spinal cord disease from a different mechanism in a different decade.

The three conversations in this post take place in Houston, San Antonio, and Dallas — in the outpatient pediatric neurometabolic clinics of Texas children’s hospitals serving Spanish-speaking working-class families whose sons were identified by newborn screening or family cascade testing after an elder sibling’s X-ALD diagnosis. Each family arrived at their misunderstanding through a reasonable inference from accurate but incomplete information. The pediatric peroxisomal disorders nurse who can explain the mechanism specifically enough that the family understands why their intuition is wrong in this case — not just that it is wrong — is the clinician who prevents the delayed scans, the untested adrenal deteriorations, and the unrealized female-carrier risk conversations that determine outcomes in X-ALD families for generations.

Scenario 1: Miguel Sánchez-Torres — Houston, Texas

Pediatric neurometabolic nurse Lupe Cisneros-Vega and the parents who cannot understand why a brain MRI every six months is required when their son is completely normal

Miguel is nine years old. He lives in Houston with Carmen Sánchez-Molina, thirty-eight, an insurance adjuster, and Héctor Torres-Vega, forty-two, a warehouse manager. Miguel was identified as having X-ALD three years ago, at age six, when his elder brother Ernesto — then ten — was diagnosed with childhood cerebral ALD after behavioral changes and declining school performance led to an MRI showing parieto-occipital white-matter signal change (Loes score 7). Ernesto received hematopoietic stem cell transplantation within six weeks of diagnosis; now eleven, he is neurologically stable with a Loes score that has not progressed in fourteen months. After Ernesto’s diagnosis, cascade testing of the family confirmed that Carmen carries the ABCD1 c.796C>T p.Arg266Cys mutation on one X chromosome, and that Miguel, then six, is hemizygous for the same mutation. Plasma VLCFA: C26:0 2.8 μg/mL (elevated; normal <1.3), C24:0/C22:0 ratio 2.1 (elevated; normal <1.5). ACTH stimulation test: cortisol peak 14 μg/dL — borderline, not yet requiring hydrocortisone, but monitored. Brain MRI at age six: Loes score 0. Brain MRI at age seven: Loes score 0. Brain MRI at age eight: Loes score 0. Brain MRI scheduled today at age nine.

Miguel attends a Houston elementary school, earns academic honors each semester, plays recreational soccer in a Saturday league, and shows no neurological symptoms. Carmen and Héctor have driven Miguel to the MRI unit six times over three years — each time watching him lie still in the scanner for forty minutes, each time receiving a phone call three days later with a normal result. Before today’s appointment, Carmen raised the question she has been carrying for months.

Carmen: “Enfermera Cisneros-Vega, quiero preguntarle algo que tengo en la mente desde hace tiempo. Llevamos tres años haciendo la resonancia cada seis meses. Cada vez sale normal. Miguel está bien — mejor que bien. Hace deporte, saca buenas notas, no tiene ningun síntoma. ¿Por qué seguimos haciendo la resonancia cada seis meses? ¿No seria suficiente hacerla una vez al año? Ya vimos que Ernesto se enfermó porque su tumor no fue detectado a tiempo. ¿Si Miguel está bien, por qué necesitamos seguir tan seguido?”

(Nurse Cisneros-Vega, I want to ask you something I have had in my mind for a while. We have been doing the MRI every six months for three years. Every time it comes back normal. Miguel is fine — better than fine. He plays sports, he gets good grades, he has no symptoms. Why do we keep doing the MRI every six months? Would it not be enough to do it once a year? We already saw that Ernesto got sick because his disease was not detected in time. If Miguel is fine, why do we need to keep going so frequently?)

Héctor: “Entiendo que antes era más urgente porque Ernesto estaba enfermándose. Pero Miguel no muestra ningún problema. ¿No podemos relajar un poco la vigilancia?”

(I understand that before it was more urgent because Ernesto was getting sick. But Miguel shows no problems. Can we not relax the surveillance a little?)

Nurse Lupe Cisneros-Vega recognizes that this family has internalized exactly the lesson they should have learned from Ernesto — early detection saved him — and is now misapplying it to Miguel’s situation by concluding that consecutive normal MRIs imply reduced future risk. She begins with the mechanism of what the surveillance is actually watching for. “Quiero explicarles algo importante sobre la resonancia de Miguel — algo que es diferente de la mayoría de los exámenes médicos. La resonancia de Miguel no está vigilando síntomas. No buscamos que Miguel se vea peor ni que su rendimiento escolar baje. Si esperáramos eso, ya sería demasiado tarde. Lo que busca la resonancia es un cambio en la imagen — en la sustancia blanca del cerebro — que aparece meses antes de que Miguel sienta o muestre cualquier cosa. Eso es lo crítico.”

(I want to explain something important about Miguel’s MRI — something that is different from most medical tests. Miguel’s MRI is not monitoring symptoms. We are not looking for Miguel to look worse or for his school performance to decline. If we waited for that, it would already be too late. What the MRI looks for is a change in the image — in the brain’s white matter — that appears months before Miguel feels or shows anything. That is what is critical.)

Carmen: “¿Meses antes? ¿Entonces el cerebro puede estar cambiando aunque él se vea perfectamente bien?”

(Months before? So the brain can be changing even though he looks perfectly fine?)

“Exactamente. Eso es lo que pasó con Ernesto. La resonancia de Ernesto mostró el primer cambio — una pequeña área de señal diferente en la parte posterior del cerebro — antes de que los maestros notaran algún cambio en su comportamiento. Si Ernesto hubiera tenido la resonancia cuatro meses después de cuando la tuvo, ese primer cambio habría avanzado al punto donde el trasplante ya no funcionaría. El trasplante funcionó en Ernesto porque lo encontramos a tiempo. Para Miguel, la pregunta es: ¿cuánto tiempo tenemos entre el primer cambio y el momento en que ya no podemos intervenir? La respuesta, basada en lo que sabemos de la enfermedad, es aproximadamente seis meses en los casos que avanzan rápidamente — a veces un año, pero no siempre. Si hiciéramos la resonancia una vez al año, y el cambio empezara a los tres meses después de la última resonancia normal, lo veríamos nueve meses después — posiblemente demasiado tarde.”

(Exactly. That is what happened with Ernesto. Ernesto’s MRI showed the first change — a small area of different signal in the back of the brain — before the teachers noticed any change in his behavior. If Ernesto had had the MRI four months later than when he did, that first change would have progressed to the point where the transplant no longer worked. The transplant worked for Ernesto because we found it in time. For Miguel, the question is: how much time do we have between the first change and the moment we can no longer intervene? The answer, based on what we know about the disease, is approximately six months in cases that advance rapidly — sometimes a year, but not always. If we did the MRI once a year, and the change started three months after the last normal MRI, we would see it nine months later — possibly too late.)

Héctor: “¿Y Miguel tiene más riesgo que Ernesto?”

(And is Miguel at higher risk than Ernesto?)

“Esa es una pregunta muy importante. Miguel y Ernesto tienen la misma mutación en el gen ABCD1. Ningún marcador en sangre nos dice cuál de los dos va a desarrollar la forma infantil y cuál no. El nivel de los ácidos grasos en la sangre de Miguel está elevado — como el de Ernesto. Pero tener ácidos grasos elevados no predice si va a haber inflamación en el cerebro ni cuándo. Aproximadamente el treinta y cinco por ciento de los niños varones con la mutación de Miguel desarrollan la forma infantil entre los cuatro y los doce años. Que Miguel lleve tres años con resonancias normales no reduce ese porcentaje. Cada resonancia es una nueva evaluación de su estado en ese momento — no una confirmación de que el riesgo bajó. El hecho de que Ernesto haya tenido la forma infantil no aumenta el riesgo de Miguel ni lo reduce. Son dos niños con la misma mutación y el mismo riesgo estadístico, viviendo en el mismo cuerpo diferente.”

(That is a very important question. Miguel and Ernesto have the same mutation in the ABCD1 gene. No blood marker tells us which of them will develop the childhood form and which will not. Miguel’s plasma fatty acid level is elevated — like Ernesto’s was. But having elevated fatty acids does not predict whether there will be brain inflammation or when. Approximately thirty-five percent of boys with Miguel’s mutation develop the childhood form between ages four and twelve. The fact that Miguel has had three years of normal MRIs does not reduce that percentage. Each MRI is a new evaluation of his current status — not a confirmation that the risk has gone down. The fact that Ernesto had the childhood form does not increase or decrease Miguel’s risk. They are two boys with the same mutation and the same statistical risk, living in the same different body.)

Carmen: “Entonces las resonancias normales no nos dicen que está fuera de peligro. Solo nos dicen que hasta ahora está bien.”

(So the normal MRIs do not tell us he is out of danger. They only tell us that until now he is well.)

“Exactamente. Cada resonancia normal de Miguel nos dice que hasta ese momento no hay inflamación en el cerebro. No nos dice lo que va a pasar en los próximos seis meses. El intervalo de seis meses es el máximo que podemos esperar con seguridad — no es que estamos siendo precavidos de más. Es que si esperamos más, arriesgamos que el cambio avance hasta donde el trasplante ya no funcione. Miguel tiene ahora nueve años. El riesgo más alto de la forma infantil es entre los cuatro y los doce años. Estamos en el corazón de esa ventana. Cuando cumpla doce o trece años, la frecuencia de la resonancia puede cambiar a una vez al año, porque el riesgo de la forma infantil baja significativamente después de los doce. Pero ahora mismo, el intervalo de seis meses no es negociable.”

(Exactly. Each normal MRI of Miguel tells us that up to that moment there is no brain inflammation. It does not tell us what will happen in the next six months. The six-month interval is the maximum we can safely wait — it is not that we are being overly cautious. It is that if we wait longer, we risk the change advancing to where the transplant no longer works. Miguel is nine years old now. The highest risk for the childhood form is between ages four and twelve. We are in the heart of that window. When he turns twelve or thirteen, the MRI frequency can change to once a year, because the risk of the childhood form falls significantly after twelve. But right now, the six-month interval is non-negotiable.)

Six months later, Miguel’s MRI shows Loes score 0 for the seventh consecutive time. Héctor calls from the parking lot afterward. “Entendemos ahora por qué hay que venir. No es que algo esté mal — es que si esperamos a que algo esté mal, la opción de arreglarlo se habrá ido. El próximo control de seis meses lo vamos a tener marcado en el calendario desde hoy.” (“We understand now why we have to come. It is not that something is wrong — it is that if we wait until something is wrong, the option to fix it will be gone. We are going to mark the next six-month check on the calendar starting today.”)

Scenario 2: Alejandro Vargas-Morales — San Antonio, Texas

Pediatric neurometabolic nurse Blanca Herrera-Fuentes and the parents who cannot understand why annual ACTH testing continues when their son looks completely healthy and has never had a crisis

Alejandro is seven years old. He lives in San Antonio with Lucía Vargas-Cruz, thirty-four, an elementary school teacher, and Rodrigo Morales-Reyes, thirty-nine, a truck driver. Alejandro was identified at three weeks of age via the Texas newborn screening expanded panel, which includes plasma C26:0 measurement for X-ALD screening. Elevated C26:0 at 2.1 μg/mL led to confirmatory VLCFA profile and molecular testing: ABCD1 hemizygous c.1415delG frameshift mutation, confirmed pathogenic. Brain MRI at age three: Loes score 0. Brain MRI at age four: Loes score 0. Brain MRI at age five: Loes score 0. Brain MRI at age six: Loes score 0. Brain MRI at age seven (today): Loes score 0 — five consecutive normal scans. ACTH stimulation test at age five: cortisol peak 13 μg/dL — borderline partial adrenal insufficiency, not yet meeting threshold for replacement; hydrocortisone held, repeat ACTH test in one year ordered. ACTH stimulation test at age seven (today): cortisol peak 8 μg/dL — confirming primary adrenal insufficiency. Hydrocortisone 7 mg/m²/day and fludrocortisone 0.1 mg/day started three months ago. Today’s clinic visit is the first full follow-up since starting hormone replacement.

Alejandro appears completely healthy. He started second grade last month. His growth velocity is normal, his blood pressure is 90/58 mmHg, his sodium and potassium are within normal limits on fludrocortisone. He has had no adrenal crisis. Lucía and Rodrigo are grateful for the normal brain MRI but confused about the adrenal testing schedule: the metabolic team has told them that another ACTH stimulation test will be needed in one year.

Lucía: “Enfermera Herrera-Fuentes, ya sé que la prueba de ACTH mostró que la glándula suprarrenal de Alejandro no funciona bien y que por eso empezamos el hidrocortisona. Eso lo entendemos. Lo que no entendemos es por qué hay que seguir haciendo la prueba cada año. Si ya sabemos que la glándula no funciona y ya le estamos dando el hidrocortisona, ¿qué más va a cambiar? Alejandro se ve perfectamente bien. En tres meses con el hidrocortisona, no ha pasado nada malo.”

(Nurse Herrera-Fuentes, I already know that the ACTH test showed that Alejandro’s adrenal gland does not function well and that is why we started the hydrocortisone. That we understand. What we do not understand is why we have to keep doing the test every year. If we already know the gland does not work and we are already giving him hydrocortisone, what else is going to change? Alejandro looks perfectly fine. In three months on hydrocortisone, nothing bad has happened.)

Rodrigo: “Y las resonancias del cerebro siguen saliendo normales. ¿No significa eso que la enfermedad está controlada?”

(And the brain MRIs keep coming back normal. Does that not mean the disease is controlled?)

Nurse Blanca Herrera-Fuentes understands that this family has correctly connected three months of stable hydrocortisone replacement with Alejandro’s current wellbeing, and has reasonably concluded that an annual retest might be redundant. She begins by separating the adrenal disease from the neurological disease. “Quiero explicarles algo sobre la enfermedad de Alejandro que es muy importante: la enfermedad de la glándula suprarrenal y la enfermedad del cerebro son dos procesos diferentes en el cuerpo de Alejandro. Las resonancias del cerebro normales nos dicen que el proceso inflamatorio del cerebro no ha empezado todavía. Eso es una muy buena noticia y es exactamente lo que queremos. Pero las resonancias del cerebro no nos dicen nada sobre lo que está pasando en la glándula suprarrenal. Son dos enfermidades que están ocurriendo en paralelo — en tejidos diferentes, causadas por el mismo mecanismo básico pero progresando de forma independiente.”

(I want to explain something about Alejandro’s disease that is very important: the adrenal gland disease and the brain disease are two different processes in Alejandro’s body. The normal brain MRIs tell us that the brain’s inflammatory process has not started yet. That is very good news and is exactly what we want. But the brain MRIs tell us nothing about what is happening in the adrenal gland. They are two diseases occurring in parallel — in different tissues, caused by the same basic mechanism but progressing independently.)

Lucía: “¿Y qué le está pasando a la glándula suprarrenal?”

(And what is happening to the adrenal gland?)

“Los mismos ácidos grasos que se acumulan en la sustancia blanca del cerebro de Alejandro — los ácidos grasos de cadena muy larga — también se acumulan en las células de la corteza suprarrenal. La corteza suprarrenal tiene varias capas de células que producen el cortisol, la aldosterona, y otras hormonas. Los ácidos grasos de cadena muy larga van acumulándose en las células de la zona que produce el cortisol, y esa acumulación mata esas células progresivamente — año tras año, independientemente de cómo estén las resonancias del cerebro. Cuando hicimos la primera prueba de ACTH, la glándula todavía respondía algo — 13 microgramos por decilitro, por debajo de lo normal pero todavía respondiendo. Dos años después, la prueba muestra 8 — la glándula responde menos. Eso nos confirma que el proceso de destrucción continúa. Ahora bien, cuando empezamos el hidrocortisona, Alejandro se ve bien porque el hidrocortisona está haciendo el trabajo que la glándula no puede hacer. Pero la glándula sigue perdiendo células. El hidrocortisona no detiene la destrucción — solo reemplaza lo que falta. El año que viene, puede que la glándula produzca aún menos. La prueba anual de ACTH nos dice cuánto ha cambiado la respuesta de la glándula para que podamos ajustar la dosis del hidrocortisona.”

(The same fatty acids that accumulate in Alejandro’s brain white matter — the very-long-chain fatty acids — also accumulate in the cells of the adrenal cortex. The adrenal cortex has several layers of cells that produce cortisol, aldosterone, and other hormones. The very-long-chain fatty acids accumulate in the cells of the zone that produces cortisol, and that accumulation kills those cells progressively — year after year, regardless of how the brain MRIs are. When we did the first ACTH test, the gland still responded somewhat — 13 micrograms per deciliter, below normal but still responding. Two years later, the test shows 8 — the gland responds less. That confirms that the destruction process continues. Now, when we started the hydrocortisone, Alejandro looks well because the hydrocortisone is doing the work the gland cannot do. But the gland continues losing cells. Hydrocortisone does not stop the destruction — it only replaces what is missing. Next year, the gland may produce even less. The annual ACTH test tells us how much the gland’s response has changed so we can adjust the hydrocortisone dose.)

Rodrigo: “¿Y si no hicieramos la prueba?”

(And if we did not do the test?)

“Si no hiciéramos la prueba, no sabríamos que la glándula está respondiendo menos cada año. La dosis del hidrocortisona que Alejandro está recibiendo ahora es la correcta para el nivel de función que la glándula tiene ahora. Si la glándula sigue perdiendo células y la dosis no se ajusta, puede que el año que viene, durante una enfermedad importante, la dosis ya no sea suficiente. Y esto es lo más importante que quiero que entiendan sobre el hidrocortisona: en una enfermedad con fiebre o con vómitos, el cuerpo necesita tres veces más cortisol de lo normal. Cuando Alejandro tenga una gripe con fiebre o un vómito repetido, tendrá que tomar el triple de la dosis habitual del hidrocortisona ese día — eso se llama la dosis de estrés. Si no lo hace, el cuerpo va a necesitar cortisol para mantener la presión arterial y el azúcar en la sangre durante la enfermedad, no lo va a tener, y Alejandro puede entrar en crisis suprarrenal — un descenso rápido de la presión arterial y la glucosa que puede ser grave en horas. La prueba anual nos asegura que la dosis base que usamos para calcular la dosis de estrés sea la correcta.”

(If we did not do the test, we would not know that the gland is responding less each year. The hydrocortisone dose Alejandro is receiving now is correct for the level of function the gland has now. If the gland continues losing cells and the dose is not adjusted, it may be that next year, during a significant illness, the dose is no longer sufficient. And this is the most important thing I want you to understand about the hydrocortisone: during an illness with fever or vomiting, the body needs three times more cortisol than normal. When Alejandro has a flu with fever or repeated vomiting, he will need to take triple the usual hydrocortisone dose that day — that is called the stress dose. If he does not, the body will need cortisol to maintain blood pressure and blood sugar during the illness, will not have it, and Alejandro can enter adrenal crisis — a rapid fall in blood pressure and glucose that can be serious within hours. The annual test ensures that the base dose we use to calculate the stress dose is correct.)

Lucía: “Entonces el hidrocortisona está funcionando bien ahora — pero la glándula sigue empeorando por debajo, y si no chequeamos, no sabremos cuándo la dosis ya no sea suficiente.”

(So the hydrocortisone is working well now — but the gland continues worsening underneath, and if we do not check, we will not know when the dose is no longer sufficient.)

“Exactamente. Alejandro se ve bien porque el tratamiento está funcionando. La prueba anual mide el estado de la glándula que el tratamiento está reemplazando — no para descontinuar el tratamiento, sino para asegurarnos de que la dosis esté bien calibrada. Y también para chequear la parte de la glándula que produce aldosterona — la hormona que controla el sodio y el potasio. Esa parte se destruye más lentamente que la que produce el cortisol, pero también puede deteriorarse con tiempo. La fludrocortisona que Alejandro toma es para la aldosterona. Si esa parte también empeora, la dosis de fludrocortisona necesitará ajustarse también. Todo eso lo rastreamos año a año.”

(Exactly. Alejandro looks well because the treatment is working. The annual test measures the state of the gland that the treatment is replacing — not to discontinue the treatment, but to make sure the dose is well calibrated. And also to check the part of the gland that produces aldosterone — the hormone that controls sodium and potassium. That part is destroyed more slowly than the part that produces cortisol, but it can also deteriorate over time. The fludrocortisone Alejandro takes is for the aldosterone. If that part also worsens, the fludrocortisone dose will also need to be adjusted. We track all of that year by year.)

At the one-year ACTH retest, Alejandro’s cortisol peak is 6 μg/dL. The hydrocortisone dose is adjusted to 8.5 mg/m²/day. Brain MRI: Loes score 0 for the sixth consecutive time. Lucía: “Cuando vemos los números lado a lado — 13, 8, 6 — se ve claramente que la glándula está cediendo poco a poco aunque Alejandro no se vea nada diferente. Ahora entendemos: las resonancias miden el cerebro. La prueba de ACTH mide la glándula. Son dos cosas completamente diferentes, y necesitamos las dos.” (“When we see the numbers side by side — 13, 8, 6 — it is clearly visible that the gland is slowly giving way even though Alejandro looks no different. Now we understand: the MRIs measure the brain. The ACTH test measures the gland. They are two completely different things, and we need both.”)

Scenario 3: Sofía Reyes-García — Dallas, Texas

Pediatric neurometabolic nurse Silvia Morales-Cruz and the parents who cannot understand why their daughter needs neurological follow-up when she was told girls cannot get X-ALD

Sofía is fourteen years old. She lives in Dallas with Esperanza Reyes-Morales, forty-one, a dental hygienist, and Gabriel García-Espinoza, forty-five, a high school biology teacher. Sofía’s younger brother Tomás, now eleven, was diagnosed with X-ALD at age nine after a school wellness screening flagged declining reading comprehension; MRI at that time showed Loes score 5 in the parieto-occipital white matter. Tomás received hematopoietic stem cell transplantation and is neurologically stable. After Tomás’s diagnosis and treatment, cascade family testing confirmed that Esperanza carries the ABCD1 c.796C>T mutation. At age twelve, Sofía’s ABCD1 carrier status was confirmed: she is heterozygous for the same mutation. Plasma VLCFA: C26:0 1.6 μg/mL (mildly elevated; normal <1.3, with female carriers typically showing mild elevation rather than the pronounced elevation seen in hemizygous males). ACTH stimulation test: cortisol peak 21 μg/dL — completely normal. Neurological examination: normal gait, normal reflexes throughout, normal plantar responses, intact sensation to vibration and proprioception in the feet. Sofía is a healthy, active teenager in ninth grade.

At Tomás’s diagnosis, the genetics counselor summarized X-ALD inheritance for the family and included the statement that girls carry the mutation but generally do not develop the childhood brain disease. Esperanza and Gabriel internalized that accurately for Tomás’s form of the disease. Now, two years after Sofía’s carrier status was confirmed, they are sitting in her second annual neurometabolic clinic visit and are still unclear about its purpose.

Esperanza: “Enfermera Morales-Cruz, cuando le diagnosticaron a Tomás, nos dijeron que las niñas pueden llevar el gen pero no les da la enfermedad del cerebro. Sofía salió portadora, pero su cerebro está bien — la neurologa lo dijo en la última visita. La prueba de ACTH también salió normal. ¿Por qué Sofía sigue viniendo a esta clínica cada año si no tiene la enfermedad?”

(Nurse Morales-Cruz, when Tomás was diagnosed, they told us that girls can carry the gene but do not get the brain disease. Sofía came out as a carrier, but her brain is fine — the neurologist said so at the last visit. The ACTH test also came back normal. Why does Sofía keep coming to this clinic every year if she does not have the disease?)

Gabriel: “Entiendo la importancia de seguir a Tomás de cerca. Pero Sofía está sana. ¿No es el seguimiento anual para los que tienen la enfermedad activa?”

(I understand the importance of following Tomás closely. But Sofía is healthy. Is annual follow-up not for those who have the active disease?)

Nurse Silvia Morales-Cruz understands that this family received accurate information about one dimension of X-ALD in females and accurate information that is silent about a different dimension. She begins by confirming what they were told before expanding it. “Lo que les dijeron sobre Sofía y la enfermedad del cerebro es correcto. La forma infantil — la que afectó a Tomás entre los nueve y los diez años, con la inflamación rápida en la sustancia blanca del cerebro — casi exclusivamente les ocurre a los niños que son hemicigotos, es decir, que tienen la mutación en el único cromosoma X que tienen. Sofía tiene dos cromosomas X. En uno está la mutación. En el otro está la copia normal. Eso la protege de la forma infantil que tuvo Tomás. Eso es correcto y no ha cambiado. Lo que quiero explicarles hoy es la parte de la historia que no se explicó en esa primera conversación, porque no era relevante para Tomás en ese momento pero sí es relevante para Sofía a largo plazo.”

(What they told you about Sofía and the brain disease is correct. The childhood form — the one that affected Tomás between nine and ten years old, with the rapid inflammation in the brain white matter — almost exclusively occurs in boys who are hemizygous, meaning they have the mutation on the only X chromosome they have. Sofía has two X chromosomes. On one is the mutation. On the other is the normal copy. That protects her from the childhood form that Tomás had. That is correct and has not changed. What I want to explain to you today is the part of the story that was not explained in that first conversation, because it was not relevant to Tomás at that moment but is relevant for Sofía in the long term.)

Esperanza: “¿Qué parte?”

(What part?)

“En la enfermedad de Tomás, la mutación está en el único cromosoma X que él tiene, entonces todas las células de su cuerpo usan esa versión defectuosa de la proteína. Los ácidos grasos se acumulan en todas partes, sin excepción. En Sofía, cada célula de su cuerpo tiene dos cromosomas X. En cada célula, uno de los dos cromosomas X se desactiva al azar — este proceso ocurre durante el desarrollo embrionario y se llama inactivación del cromosoma X. Las células donde el cromosoma X normal está activo producen la proteína ALD funcional y no tienen problemas con los ácidos grasos. Las células donde el cromosoma X con la mutación está activo no producen la proteína funcional y acumulan ácidos grasos. En el cuerpo de Sofía, estas dos poblaciones de células coexisten — algunas funcionan normal, otras acumulan los ácidos grasos. Eso es por qué la forma infantil del cerebro no aplica a Sofía: esa forma necesita la acumulación masiva y sostenida que solo ocurre cuando todas las células tienen la mutación. Pero hay otra forma de la enfermedad, llamada adrenomieloneuropatía, que afecta la médula espinal y no requiere esa acumulación máxima.”

(In Tomás’s disease, the mutation is on the only X chromosome he has, so all the cells in his body use that defective version of the protein. Fatty acids accumulate everywhere, without exception. In Sofía, each cell in her body has two X chromosomes. In each cell, one of the two X chromosomes is randomly inactivated — this process occurs during embryonic development and is called X-chromosome inactivation. The cells where the normal X chromosome is active produce functional ALD protein and have no problem with fatty acids. The cells where the X chromosome with the mutation is active do not produce functional protein and accumulate fatty acids. In Sofía’s body, these two cell populations coexist — some function normally, others accumulate the fatty acids. That is why the childhood brain form does not apply to Sofía: that form needs the massive, sustained accumulation that only occurs when all cells have the mutation. But there is another form of the disease, called adrenomyeloneuropathy, that affects the spinal cord and does not require that maximum accumulation.)

Gabriel: “¿Adrenomieloneuropatía? ¿Eso puede afectar a Sofía?”

(Adrenomyeloneuropathy? Can that affect Sofía?)

“Sí. La adrenomieloneuropatía es la forma de la enfermedad que afecta los axones largos de la médula espinal — los que llevan las señales desde el cerebro hasta las piernas y desde las piernas hasta el cerebro. En los hombres con la mutación de Tomás que sobreviven la niñez sin la forma del cerebro, prácticamente todos desarrollan alguna forma de esta enfermedad de la médula espinal entre los veinte y los cuarenta años. En las mujeres portadoras como Sofía, aproximadamente el sesenta y cinco por ciento desarrolla síntomas — generalmente rigidez progresiva en las piernas, dificultad para caminar, urgencia urinaria, y pérdida de sensación en los pies — antes de los sesenta años. Esta forma avanza más lentamente en las mujeres que en los hombres, porque las mujeres tienen la proteccíon parcial de las células que usan el cromosoma X normal. Pero avanza. Y los primeros síntomas tieneden a aparecer entre los treinta y los cuarenta años, no en la adolescencia.”

(Yes. Adrenomyeloneuropathy is the form of the disease that affects the long axons of the spinal cord — the ones that carry signals from the brain to the legs and from the legs to the brain. In men with Tomás’s mutation who survive childhood without the brain form, essentially all develop some form of this spinal cord disease between ages twenty and forty. In female carriers like Sofía, approximately sixty-five percent develop symptoms — generally progressive leg stiffness, difficulty walking, urinary urgency, and sensory loss in the feet — before age sixty. This form progresses more slowly in women than in men, because women have the partial protection of the cells that use the normal X chromosome. But it progresses. And the first symptoms tend to appear between ages thirty and forty, not in adolescence.)

Esperanza: “¿Entonces el seguimiento anual ahora — cuando Sofía tiene catorce años y está completamente bien — es para una enfermedad que puede aparecer en veinte años?”

(So the annual follow-up now — when Sofía is fourteen years old and is completely well — is for a disease that may appear in twenty years?)

“En parte, sí. La razón principal de los controles de Sofía ahora es establecer su línea de base — cómo camina, cómo son sus reflejos, cómo está la sensación en sus pies — de forma que cuando Sofía tenga treinta y cinco años y vaya a un neurólogo con rigidez en las piernas, ese neurólogo tenga la documentación de cómo era el sistema nervioso de Sofía a los catorce, a los dieciséis, a los dieciocho años. Eso permite detectar el cambio temprano. Sin ese historial, los primeros cambios son difíciles de distinguir del envejecimiento normal. Pero hay otra parte del seguimiento de Sofía que no es para el futuro — es para ahora. Sofía va a ser adulta en pocos años. Cuando decida tener hijos, cada hijo varón que tenga tendrá un cincuenta por ciento de probabilidad de heredar la mutación de Sofía y estar en el riesgo que tuvo Tomás. Existen opciones para eso — diagnóstico genético preimplantatorio, diagnóstico prenatal — que requieren pensar y planificar con antelación. El trabajo que hacemos con Sofía ahora en esta clínica es asegurarnos de que cuando llegue el momento de esa conversación, Sofía y ustedes entienden exactamente qué significa su estado de portadora para la siguiente generación.”

(In part, yes. The main reason for Sofía’s check-ups now is to establish her baseline — how she walks, how her reflexes are, how sensation is in her feet — so that when Sofía is thirty-five years old and goes to a neurologist with leg stiffness, that neurologist has documentation of how Sofía’s nervous system was at fourteen, sixteen, eighteen years old. That allows detecting the change early. Without that history, the first changes are difficult to distinguish from normal aging. But there is another part of Sofía’s follow-up that is not for the future — it is for now. Sofía will be an adult in a few years. When she decides to have children, each son she has will have a fifty percent chance of inheriting Sofía’s mutation and being at the risk Tomás faced. Options exist for that — preimplantation genetic testing, prenatal diagnosis — that require thinking and planning in advance. The work we do with Sofía now in this clinic is to ensure that when the time comes for that conversation, Sofía and you understand exactly what her carrier status means for the next generation.)

Gabriel — a biology teacher — nodded slowly. “Entonces 'ser portadora' no significa 'no tener la enfermedad.' Significa tener una enfermedad diferente que empieza más tarde y avanza más lento. Y tener que pensar en lo que significa para los hijos de Sofía.”

(So 'being a carrier' does not mean 'not having the disease.' It means having a different disease that starts later and progresses more slowly. And having to think about what it means for Sofía’s children.)

“Eso es exactamente correcto. Ser portadora de la mutación ABCD1 significa tener un riesgo real de enfermedad de la médula espinal en la edad adulta, y tener hijos que están en el mismo riesgo que tuvo Tomás. Ninguna de las dos cosas es inevitable. Pero las dos merecen seguimiento y planificación. Lo que la clínica de Sofía hace cada año es preparar a Sofía — y a ustedes — para tener esas conversaciones con todo el contexto que necesitan para tomarlas bien.”

(That is exactly right. Being a carrier of the ABCD1 mutation means having a real risk of spinal cord disease in adulthood, and having children who face the same risk Tomás faced. Neither of those things is inevitable. But both deserve follow-up and planning. What Sofía’s clinic does every year is prepare Sofía — and you — to have those conversations with all the context needed to navigate them well.)

At the following year’s annual visit, Sofía brings her own notebook with questions she has written down. She has read about X-ALD online and has asked the clinic to recommend resources in Spanish for her. Esperanza: “Sofía ya entiende que ella tiene su propia versión de la enfermedad de Tomás — diferente, pero real. Ya no preguntamos por qué viene a la clínica. Preguntamos qué sigue.” (“Sofía already understands that she has her own version of Tomás’s disease — different, but real. We no longer ask why she comes to the clinic. We ask what is next.”)